ADC Therapeutics

ADC Therapeutics is a commercial-stage biotechnology company based in Epalinges, Switzerland, that develops targeted antibody-drug conjugates for the treatment of hematological malignancies and solid tumors. The publicly traded enterprise operates with a workforce of approximately 300 employees and has raised roughly $641 million across multiple funding rounds, including a $267 million initial public offering on the New York Stock Exchange. Its business model centers on the commercialization of oncology therapeutics, generating approximately $69 million in net product sales during 2023 from its primary FDA-approved drug, ZYNLONTA. The organization expands its global distribution and clinical research capabilities through strategic licensing agreements and partnerships with prominent pharmaceutical entities such as Sobi and AstraZeneca, alongside early institutional backing from Auven Therapeutics. ADC Therapeutics was founded in 2011 by Chris Martin, Stephen Evans-Freke, and Dr. Peter B. Corr.